All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Erlonat 150mg Tablet
Prescription Required
Salt Composition : Erlotinib
Manufacturer : NATCO PHARMA LTD
Origin of Medicine : India
30 Tablet(s) In A Bottle
Introduction to Erlonat 150mg Tablet
Erlonat 150mg Tablet is an anticancer medicine. Cancer is an abnormal and uncontrolled multiplication of cells within the body. It is used in the treatment of patients with advanced or metastatic non-small cell lung cancer.
Erlonat 150mg Tablet is given in combination with Gemcitabine to treat pancreas cancer at the metastatic stage. Administration of this medicine may lead to kidney and liver failure. The doctor will periodically monitor your kidney and liver function. Inform your physician if you have any clotting disorders or medicines taken for clotting disorders, as the Erlonat 150mg Tablet may increase the tendency to bleed.
Inform your physician if you develop pain in the eye, blurred vision, cough, fever, shortness of breath, severe abdominal pain, and persistent diarrhea while taking this medicine. You are advised not to smoke while treated with this medicine, as smoking may decrease the amount of medicine in the blood. Wear protective clothing and sunscreen while going outside.
Uses of Erlonat 150mg Tablet
- Advanced or metastatic non-small lung cancer (NSCLC)
- Advanced or metastatic pancreatic cancer
Therapeutic Effects of Erlonat 150mg Tablet
Erlonat 150mg Tablet prevents the activity of a protein called epidermal growth factor receptor (EFGR), a protein involved in the spread and growth of cancer cells.
Interaction of Erlonat 150mg Tablet with other drugs
Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional and vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with Erlonat150 mg tablet and cause undesirable side effects.
More Information about Erlonat 150mg Tablet
Keep out of sight and reach of children. Store at a controlled room temperature between 15°C to 30°C. Do not freeze.
How to consume Erlonat 150mg Tablet
Always take this medicine as prescribed by the doctor. The tablet must be taken at least one hour before or two hours after taking food. Contact your doctor if you missed the dose or taken more.
Safety Advices for Erlonat 150mg Tablet
Pregnancy
Taking an Erlonat 150mg Tablet while pregnant can harm the baby. You should not take this medicine during pregnancy unless your doctor recommends taking it. Inform your doctor if you are pregnant or planning to be pregnant before taking this medicine.
Breast Feeding
You must not take an Erlonat 150mg Tablet if you are breastfeeding. Consult your doctor for risks and benefits.
Lungs
It is unknown whether Erlonat 150 Tablets affect the lungs. Please consult your doctor.
Liver
This medicine is not recommended in patients with severe liver diseases. Inform your physician if you have any liver disorders.
Alcohol
It is unknown whether it is safe to consume alcohol with Erlonat 150 mg Tablets. Please consult your doctor.
Driving
It is not known whether Erlonat 150 mg Tablet alters the ability to drive. Do not drive if you experience symptoms affecting your ability to concentrate and react.
Side Effects of Erlonat 150mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.
Serious:
- Persistent or severe diarrhea
- Pain in the eye, blurred vision
- sudden difficulty in breathing accompanied by cough and fever
- severe pain in your abdomen
- liver failure
Common:
- Rash, worsened in sun-exposed areas
- Loss of appetite decreased weight
- Infection
- Headache, changes in skin sensation
- Depression
- Nausea
- Mouth irritation
- Indigestion, stomach pain, the buildup of gas
- Hair loss, dry skin, itching
- Tiredness, fever
- Abnormal liver function
- Inflammation around fingernail
- acne, cracked skin
- bleeding from nose, stomach, intestines
- reduced kidney function
Word of Advice
Inform the doctor if the patient has vision problems, use of contact lenses, clotting disorders, intolerance to sugar, and medication is taken for cholesterol before starting this medication. This medication should not be taken along with the food, and it can be taken either before or after food as it increases the effectiveness of the medication. It is not recommended for individuals below 18 years of age. Inform the doctor about kidney and liver disorders, as this medication is not recommended in patients with kidney and liver disorders. Avoid making plans to have children or during pregnancy because this medicine is highly unsafe and causes harmful effects on the developing baby.
FAQs
Q 1. How should I take an Erlonat 150mg Tablet?
Always take this medicine as prescribed by the doctor. The tablet must be taken at least one hour before or two hours after taking food, and it should be taken at a fixed time daily.
Q 2. Does an Erlonat 150 mg Tablet cause eye dryness?
Yes, this medication can cause eye dryness and conjunctivitis, and hence patients are advised to inform the history of vision problems and use of contact lenses before taking this medication.
Q 3. Can I take an Erlonat 150 mg Tablet During pregnancy?
This medication is highly unsafe in pregnancy as it can cause harmful effects on the developing baby. Avoid making plans to have children or during pregnancy while taking this medication.
Q 4. Can I smoke while taking the Erlonat 150 mg Tablet?
Avoid smoking while taking this medication, as it can decrease the effectiveness of this medication.
Q 5. How long can I take an Erlonat 150 mg Tablet?
Erlonat 150 mg tablet is taken daily as long as prescribed by the doctor, and the duration of time varies from patient to patient depending upon the severity of the disease.
Q 6. Can Erlonat 150 mg Tablet be used in kidney disorders?
This medication is not recommended in kidney patients as it can worsen the condition of the disease.
Fact Box of Erlonat 150mg Tablet
Molecule name: Erlotinib | Therapeutic class: Tyrosine kinase inhibitor |
Pharmacological class: Anti-Neoplastics | Indications: 1. Advanced or metastatic non-small lung cancer (NSCLC) 2. Advanced or metastatic pancreatic cancer |
References
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines, 12th edition, 2011, 1735-1737.
- Mylan, Electronic medicines compendium (emc), [ Revised on Jan 2020] [ Accessed on 14th April 2021], https://www.medicines.org.uk/emc/files/pil.11264.pdf
- Genentech, US Food and Drug Administration, [ Revised on April 2010] [ Accessed on 14th April 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
